Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Prevention of NAFLD-associated HCC: Role of lifestyle and chemoprevention
Naomi F. Lange, Pompilia Radu, Jean‐François Dufour
Journal of Hepatology (2021) Vol. 75, Iss. 5, pp. 1217-1227
Open Access | Times Cited: 99

Showing 1-25 of 99 citing articles:

AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma
Amit G. Singal, Josep M. Llovet, Mark Yarchoan, et al.
Hepatology (2023) Vol. 78, Iss. 6, pp. 1922-1965
Open Access | Times Cited: 669
Global trends in hepatocellular carcinoma epidemiology: implications for screening, prevention and therapy
Amit G. Singal, Fasiha Kanwal, Josep M. Llovet
Nature Reviews Clinical Oncology (2023) Vol. 20, Iss. 12, pp. 864-884
Closed Access | Times Cited: 284
Nonalcoholic steatohepatitis-related hepatocellular carcinoma: pathogenesis and treatment
Josep M. Llovet, Catherine E. Willoughby, Amit G. Singal, et al.
Nature Reviews Gastroenterology & Hepatology (2023) Vol. 20, Iss. 8, pp. 487-503
Closed Access | Times Cited: 177
Global burden of primary liver cancer and its association with underlying aetiologies, sociodemographic status, and sex differences from 1990–2019: A DALY-based analysis of the Global Burden of Disease 2019 study
Sungchul Choi, Beom Kyung Kim, Dong Keon Yon, et al.
Clinical and Molecular Hepatology (2023) Vol. 29, Iss. 2, pp. 433-452
Open Access | Times Cited: 40
Metabolic dysfunction-associated steatotic liver disease and its link to cancer
Markos Kalligeros, Linda Henry, Zobair M. Younossi
Metabolism (2024) Vol. 160, pp. 156004-156004
Closed Access | Times Cited: 16
Effect of cofactors on NAFLD/NASH and MAFLD. A paradigm illustrating the pathomechanics of organ dysfunction
Amedeo Lonardo, Ashwani K. Singal, Natalia A. Osna, et al.
Metabolism and Target Organ Damage (2022) Vol. 2, pp. 12-12
Open Access | Times Cited: 41
MAFLD: an optimal framework for understanding liver cancer phenotypes
Harry Crane, Cameron Gofton, Ankur Sharma, et al.
Journal of Gastroenterology (2023) Vol. 58, Iss. 10, pp. 947-964
Open Access | Times Cited: 23
EASL Clinical Practice Guidelines on the management of hepatocellular carcinoma
Bruno Sangro, Lorenza Rimassa, Maxime Ronot, et al.
Journal of Hepatology (2024)
Closed Access | Times Cited: 14
Metabolic dysfunction-associated steatotic liver disease and extrahepatic gastrointestinal cancers
Alessandro Mantovani, Amedeo Lonardo, Norbert Stefan, et al.
Metabolism (2024) Vol. 160, pp. 156014-156014
Closed Access | Times Cited: 10
Phenotypes of Metabolic Dysfunction–Associated Steatotic Liver Disease–Associated Hepatocellular Carcinoma
Jesús Rivera‐Esteban, Sergio Muñoz, Mónica Higuera, et al.
Clinical Gastroenterology and Hepatology (2024) Vol. 22, Iss. 9, pp. 1774-1789.e8
Closed Access | Times Cited: 9
Statin can reduce the risk of hepatocellular carcinoma among patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis
Jie Zhang, Shifeng Fu, Deliang Liu, et al.
European Journal of Gastroenterology & Hepatology (2023) Vol. 35, Iss. 4, pp. 353-358
Closed Access | Times Cited: 18
Epidemiology, pathophysiology and clinical aspects of Hepatocellular Carcinoma in MAFLD patients
Maria Eva Argenziano, Mi Na Kim, Michele Montori, et al.
Hepatology International (2024) Vol. 18, Iss. S2, pp. 922-940
Closed Access | Times Cited: 7
Circulating fatty acids and risk of hepatocellular carcinoma and chronic liver disease mortality in the UK Biobank
Zhening Liu, Hangkai Huang, Jiarong Xie, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 6
A Machine Learning Model to Predict Risk for Hepatocellular Carcinoma in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease
Souvik Sarkar, Aniket Alurwar, Carole Ly, et al.
Gastro Hep Advances (2024) Vol. 3, Iss. 4, pp. 498-505
Open Access | Times Cited: 5
Recent advances in age-related metabolic dysfunction-associated steatotic liver disease
Qianjun He, Yifei Li, Ling-Tong Zhao, et al.
World Journal of Gastroenterology (2024) Vol. 30, Iss. 7, pp. 652-662
Open Access | Times Cited: 5
Exposure of benzo[a]pyrene induces HCC exosome‐circular RNA to activate lung fibroblasts and trigger organotropic metastasis
Wei Mu, Pengfei Gu, Huating Li, et al.
Cancer Communications (2024) Vol. 44, Iss. 7, pp. 718-738
Open Access | Times Cited: 5
Metabolic dysfunction‐associated steatotic liver disease and MetALD increases the risk of liver cancer and gastrointestinal cancer: A nationwide cohort study
Yewan Park, Jooyi Jung, Seungbong Han, et al.
Alimentary Pharmacology & Therapeutics (2024)
Open Access | Times Cited: 5
Occupational toxicants in MASLD: Bias, complexity, and future directions
Bernardo Stefanini, Francesco Tovoli
Digestive and Liver Disease (2025)
Closed Access
Hepatocellular Carcinoma Due to Nonalcoholic Fatty Liver Disease: Current Concepts and Future Challenges
Muhammad Imran Ahmad, Muhammad Umair Khan, Sudha Kodali, et al.
Journal of Hepatocellular Carcinoma (2022) Vol. Volume 9, pp. 477-496
Open Access | Times Cited: 27
Therapeutic modulation of the liver immune microenvironment
Herbert Tilg, Timon E. Adolph, Frank Tacke
Hepatology (2023)
Closed Access | Times Cited: 15
From Non-Alcoholic Steatohepatitis (NASH) to Hepatocellular Carcinoma (HCC): Epidemiology, Incidence, Predictions, Risk Factors, and Prevention
Benedetta Maria Motta, Mario Masarone, Pietro Torre, et al.
Cancers (2023) Vol. 15, Iss. 22, pp. 5458-5458
Open Access | Times Cited: 15
Integrated serum pharmacochemistry, 16S rRNA sequencing and metabolomics to reveal the material basis and mechanism of Yinzhihuang granule against non-alcoholic fatty liver disease
Yingying Tan, Zhihong Huang, Yingying Liu, et al.
Journal of Ethnopharmacology (2023) Vol. 310, pp. 116418-116418
Open Access | Times Cited: 14
Serum folate associated with nonalcoholic fatty liver disease and advanced hepatic fibrosis
Hao‐Kai Chen, Jing Luo, Xiujuan Li, et al.
Scientific Reports (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 13
Current challenges and future perspectives in treating patients with NAFLD-related cirrhosis
Maxime Mallet, Cristina Alina Silaghi, Philippe Sultanik, et al.
Hepatology (2023) Vol. 80, Iss. 5, pp. 1270-1290
Closed Access | Times Cited: 12
Statin therapy: a potential adjuvant to immunotherapies in hepatocellular carcinoma
Jiao Wang, Chengyu Liu, Rong‐Hua Hu, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 4
Page 1 - Next Page

Scroll to top